Crewe Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $458K | Buy |
7,950
+135
| +2% | +$7.75K | 0.03% | 153 |
|
|
2026
Q1 | $474K | Buy |
7,815
+58
| +0.7% | +$3.38K | 0.04% | 130 |
|
|
2025
Q4 | $418K | Buy |
7,757
+100
| +1% | +$4.81K | 0.04% | 143 |
|
|
2025
Q3 | $345K | Buy |
+7,657
| New | +$358K | 0.03% | 153 |
|
|
2024
Q3 | – | Sell |
-9,494
| Closed | -$394K | – | 751 |
|
|
2024
Q2 | $394K | Buy |
9,494
+533
| +6% | +$23.8K | 0.04% | 123 |
|
|
2024
Q1 | $486K | Buy |
+8,961
| New | +$456K | 0.06% | 102 |
|
|
2023
Q3 | – | Sell |
-9,661
| Closed | -$618K | – | 630 |
|
|
2023
Q2 | $618K | Sell |
9,661
-1,406
| -13% | -$94.3K | 0.09% | 71 |
|
|
2023
Q1 | $767K | Sell |
11,067
-309
| -3% | -$21.8K | 0.11% | 59 |
|
|
2022
Q4 | $819K | Buy |
11,376
+439
| +4% | +$33.1K | 0.13% | 57 |
|
|
2022
Q3 | $778K | Buy |
10,937
+161
| +1% | +$11.7K | 0.14% | 51 |
|
|
2022
Q2 | $830K | Buy |
10,776
+1,293
| +14% | +$98.5K | 0.18% | 39 |
|
|
2022
Q1 | $693K | Buy |
9,483
+6,133
| +183% | +$412K | 0.14% | 43 |
|
|
2021
Q4 | $209K | Buy |
3,350
+1,500
| +81% | +$88K | 0.04% | 84 |
|
|
2021
Q3 | $109K | Hold |
1,850
| – | – | 0.03% | 106 |
|
|
2021
Q2 | $124K | Sell |
1,850
-200
| -10% | -$13K | 0.03% | 103 |
|
|
2021
Q1 | $129K | Hold |
2,050
| – | – | 0.03% | 85 |
|
|
2020
Q4 | $127K | Sell |
2,050
-305
| -13% | -$18.8K | 0.05% | 82 |
|
|
2020
Q3 | $142K | Buy |
2,355
+189
| +9% | +$11.4K | 0.07% | 61 |
|
|
2020
Q2 | $127K | Sell |
2,166
-498
| -19% | -$29.8K | 0.06% | 65 |
|
|
2020
Q1 | $148K | Hold |
2,664
| – | – | 0.09% | 50 |
|
|
2019
Q4 | $171K | Buy |
2,664
+16
| +0.6% | +$916 | 0.07% | 55 |
|
|
2019
Q3 | $134K | Sell |
2,648
-39
| -1% | -$1.83K | 0.06% | 69 |
|
|
2019
Q2 | $122K | Hold |
2,687
| – | – | 0.04% | 103 |
|
|
2019
Q1 | $128K | Buy |
2,687
+39
| +1% | +$1.94K | 0.04% | 75 |
|
|
2018
Q4 | $138K | Hold |
2,648
| – | – | 0.04% | 65 |
|
|
2018
Q3 | $164K | Hold |
2,648
| – | – | 0.14% | 62 |
|
|
2018
Q2 | $147K | Hold |
2,648
| – | – | 0.14% | 60 |
|
|
2018
Q1 | $167K | Hold |
2,648
| – | – | 0.16% | 57 |
|
|
2017
Q4 | $162K | Buy |
+2,648
| New | +$166K | 0.16% | 54 |
|
Other funds holding BMY
Crewe Advisors's BMY Position: Q2 2026 in Review
Crewe Advisors increased its Bristol-Myers Squibb (BMY) stake by 1.7% in Q2 2026, buying an estimated $7.75K and bringing the position to 7,950 shares worth $458K. The position accounts for 0.03% of the portfolio, ranked #153.
Crewe Advisors first reported a position in BMY in Q4 2017 and has held it in 29 quarters since. The position peaked at $830K in Q2 2022. 2,526 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Crewe Advisors held 7,950 shares of Bristol-Myers Squibb worth $458K as of Q2 2026.
- Crewe Advisors bought 135 Bristol-Myers Squibb shares in Q2 2026, an estimated $7.75K.
- Bristol-Myers Squibb made up 0.03% of Crewe Advisors's portfolio in Q2 2026, its #153 holding.
- Crewe Advisors first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 29 quarters since.
- Crewe Advisors's Bristol-Myers Squibb position peaked at $830K in Q2 2022.
- 2,526 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.